Introduction
Gastric cancer remains a global health problem. It is still a very common tumour type in Asia, but the incidence has steadily declined during the last decades in many Western countries [1] . Gastric cancer is often diagnosed at a very advanced stage, with approximately half of all patients presenting with unresectable, locally advanced or metastatic disease. For advanced gastric cancer, the median survival is in the range of only 6-10 months, and 5-year survival rates are <10%. Even in patients with resectable disease 5-year survival is generally poor.
Metastatic gastric cancer is to be regarded as an incurable condition, and chemotherapy is usually accepted as standard palliation. A number of randomised studies in this setting have compared best supportive care strategies with intravenous chemotherapy and demonstrated that systemic treatment can actually improve overall survival and quality of life to a certain extent.
Only a small number of chemotherapeutic agents provide active palliation in this disease, including fluoropyrimidines, topoisomerase II inhibitors, anthracyclines and platinum compounds. Single-agent trials have shown that the objective response (OR) rates to drugs such as 5-fluorouracil (5-FU), mitomycin C, etoposide or cisplatin (CDDP) are usually <20%. Furthermore, the responses achieved are mainly partial and of short duration.
Combination trials have not convincingly resulted in improved survival as compared with single-agent treatment. In addition, several randomised phase III studies have failed to define a 'gold standard' combination regimen for the palliation of gastric cancer. Most commonly, combinations of CDDP and 5-FU are used for this purpose, but at present, there is no consensus regarding standard chemotherapy for patients with advanced gastric carcinoma. In a recent internet survey, 33% of participating international oncologists indicated to recommend a combination of epirubicin, CDDP and 5-FU for a typical patient with metastatic gastric cancer, while around 10-19% preferred other schedules such as 5-FU/doxorucibine/methotrexate, 5-FU/CDDP or docetaxel/CDDP plus or minus 5-FU [2] .
The objective results achievable with many of the established combinations are similar regarding the response rate and very unsatisfactory in terms of survival. More active agents are clearly needed to improve the treatment options for gastric cancer as a basis for innovative drug combinations to be used either in the palliative or perioperative setting. Recently, a number of newer compounds have been intensively studied in this tumour type. These mainly include taxanes, topoisomerase I inhibitors and oral fluoropyrimidines, as well as other agents. This review covers the most relevant drugs that have been evaluated in more recent disease-oriented trials, with specific focus on those agents for which single-agent response data are available.
Oral fluoropyrimidines
Oral prodrugs of 5-FU have been used for gastric cancer and other gastrointestinal malignancies in Japan for a very long time, and have more recently been introduced in Western countries. This group of agents includes tegafur-based drugs, such as UFT and S-1, and the tumour-activated compounds capecitabine and doxifluridine.
UFT
UFT is a fixed combination of the oral 5-FU prodrug tegafur with uracil, which acts as a competitive inhibitor of 5-FU degradation, in a 4:1 molar ratio. Uracil prevents the rapid metabolisation of 5-FU in plasma and tumour tissue by the enzyme dihydropyrimidine dehydrogenase. The drug has already been widely used in Asia, Spain and some South American countries, but is more or less a 'new' agent to many physicians in Europe, where the drug was only recently introduced for treatment of colorectal cancer. The majority of tegafur/uracil research in the field of gastric cancer has been carried out in Japan. Some of the results of these trials are difficult to interpret, as schedules and response criteria have varied widely. Only limited data is available for the combination of UFT with folinic acid (FA) for this tumour type as this approach of double modulation of tegafur was not studied systematically by Japanese investigators in earlier years. Phase II data suggest that modulated UFT has activity against gastric carcinoma similar to that seen with 5-FU, with response rates in chemotherapy-naïve patients being in the range 10-42% (Table 1 ). The tolerability of UFT is excellent as compared with bolus schedules of intravenous 5-FU.
Various combinations of UFT with other antineoplastic agents have been studied in patients with gastric cancer, mainly by Japanese, Korean and Spanish groups (Table 2) .
Furthermore, Japanese investigators have widely used UFT in combination with mitomycin C in the adjuvant and additive setting in patients with resected gastric cancer. These trials involved up to 243 patients. As postoperative treatment of gastric cancer is not regarded as routine practice in most Western countries, these data are not reported in detail.
S-1
S-1 (TS-1) is another novel combination of the 5-FU prodrug tegafur with new modulating agents, namely 5-chloro-2,4-dihydropyrimidine (gimeracil, an inhibitor of the catabolic enzyme dihydropyrimidine dehydrogenase) and potassium oxonate (oteracil, inhibiting 5-FU phosphorylation in the gastrointestinal tract) at a molar ratio of 1:0.4:1. Based on considerable response rates in Japanese trials in pre-treated and non-pre-treated patients, the drug has recently been approved for treatment of gastric cancer there (Table 3 ), but studies in the West have so far been inconclusive. The drug is currently undergoing only limited evaluation both in Europe and in the USA, as early phase II studies in gastric and colorectal cancer have not consistently confirmed the Japanese experience in terms of safety and activity of the oral compound. The toxicity profile of S-1 is similar to that of other fluoropyrimidines, but the drug was associated with significant side effects in the few disease-oriented trials in Europe.
Combinations of S-1 with CDDP are now actively being explored in Japan, based on the synergism of both agents in preclinical models. In non-pretreated patients with gastric cancer, a schedule of S-1 80 mg/m 2 given on days 1-21 and CDDP 60 mg/m 2 on day 8 of a 5 week cycle has been established in a disease-oriented phase I/II setting [16] . A high response rate of 76% was reported in 25 evaluable patients; a result that requires further confirmation.
A combination of irinotecan, CDDP and S-1 in comparison to 5-FU alone is currently being studied in a large, 450 patient randomised study using survival as the main endpoint. Another large-scale Japanese trial will compare S-1 alone with the S-1/CDDP combination [2] . Valid data from these trials are not yet available.
Capecitabine
Capecitabine is a 5-FU prodrug that was developed to reduce toxicity and improve intratumoral concentrations of the fluoropyrimidine. It is absorbed as an intact molecule from small bowel mucosa and converted sequentially in a multistep enzymatic process. The active metabolite 5-FU is generated preferably at the tumour site. The action of capecitabine does not involve inhibition of catabolic enzymes, as in the case of UFT or S-1. The drug is well tolerated, but associated with more hand-foot syndrome than the other oral fluoropyrimidines. Capecitabine is currently approved for treatment of advanced breast and colorectal cancer in many countries, but data for the tumour-activated prodrug in gastric cancer are sparse. A 19% (range 7-37%) objective response rate was reported among 31 partially pre-treated patients with gastric cancer to singleagent capecitabine given at a dose of 1657 mg/m 2 over a period 21 days [17] .
A well-tolerated two-drug combination of capecitabine 2500 mg/m 2 p.o. days 1-14 with CDDP 60 mg/m 2 given every 3 weeks was reported in preliminary form [18] . It achieved an impressive 68% (range 45-91%) response rate, that certainly requires confirmation in further trials. In another combination trial, oral capecitabine replaced the continuous infusion of 5-FU in the epirubicin/CDDP/5-FU regimen [19] . A dose of 2000 mg/m 2 p.o. was found to be tolerable and active when given for 14 days followed by 1 week rest in conjunction with the two i.v. agents administered once every 3 weeks.
Doxifluridine
Doxifluridine is an intermediate metabolite of capecitabine available in Japan and some other Asian countries. While there are no published single-agent activity data in the Western literature, the oral compound has already been used in a large adjuvant randomised Japanese trial involving 485 patients with resected gastric cancer. Patients received either doxifluridine 460 mg/m 2 /day or oral 5-FU for 2 years after curative surgery [20] . No difference in disease-free or overall survival was observed.
Like other 5-FU prodrugs, doxifluridine can be safely combined with CDDP [21] . An overall response rate of 28% (range 10-53%) was reported combining the oral fluoropyrimidine with CDDP at a dose of 70 mg/m 2 given every 4 weeks. The activity of this schedule was modest and the treatment was well tolerated.
Non-fluoropyrimidine antimetabolites Pemetrexed
Pemetrexed, a novel multi-targeted antifolate that inhibits thymidylate synthase and other folate-dependent enzymes, has been demonstrated to have activity in a wide variety of tumours. Toxicities commonly associated with the agent include neutropenia, thrombocytopenia, mucositis and diarrhoea. The compound was evaluated in 21 non-pretreated patients with gastric cancer at a dose of 500 mg/m 2 every 3 weeks in combination with folic acid. A 28% response rate was reported [22] , which appears similar to what can be achieved with antimetabolites of the fluoropyrimidine group in phase I. Other single-agent data or combination trials of pemetrexed in this tumour type have not yet been published.
Direct thymidylate synthase inhibitors Raltitrexed
Raltitrexed is a specific inhibitor of thymidylate synthase with a long plasma half-life, well-documented activity in some gastrointestinal tract malignancies and a convenient administration schedule, as the drug is usually given only once every 3 weeks. In a study comprising 33 patients with gastric cancer, however, raltitrexed given at a dose of 3 mg/m 2 did not show any antitumour activity in this tumour type.
Raltitrexed can be combined with CDDP and epirubicin in patients with unresectable tumours of the upper gastrointestinal tract [23] . A recent dose-finding study for this three-drug combination was found to be both feasible and active, and the proposed phase II dose of raltitrexed in this combination was 2.5 mg/m 2 i.v. every 3 weeks. Further disease-oriented phase I studies have been performed in patients with gastric cancer combining the direct thymidylate synthase inhibitor with platinum agents and/or anthracyclines [24] , but detailed data are not available so far.
Platinum derivatives Oxaliplatin
Oxaliplatin is a more recent platinum compound with considerable activity in a number of solid tumour entities. The drug is approved for treatment of colorectal cancer in many countries, and is associated with specific neurotoxicity and gastrointestinal side effects such as nausea and vomiting.
While there appears to be a lack of published single-agent response data in gastric cancer, oxaliplatin has already entered the field of combination chemotherapy in this tumour type. A combination of oxaliplatin with 5-FU and FA has been evaluated in a multicentric phase II setting in non-pretreated patients with gastric cancer [25] . The generally well-tolerated 'FOLFOX 6' regimen achieved a 46% response rate and a median survival of 8.5 months. Based on a number of other reports, a multi-institutional study (REAL-2 trial) with a 2 × 2 multifactorial design has been initiated in the UK, comparing the classical epirubicin/CDDP/5-FU regimen with 'EEF', where CDDP has been replaced by oxaliplatin, 'ECX', where 5-FU has been substituted by oral capecitabine and 'EEX', where both oxaliplatin and capecitabine are used in conjunction with epirubicin. This study will involve 600 patients with the primary endpoint being 1-year survival.
A recent trial has shown that objective responses can be achieved in patients with gastric cancer previously treated with CDDP-based chemotherapy, highlighting the potential lack of cross-resistance of oxaliplatin and CDDP in this setting [26] .
SKI 2053R
SKI 2053R is a newly developed platinum derivative from Korea with CDDP-like antitumour activity in pre-clinical gastric cancer models. Dose-limiting side effects are mainly hepatotoxicity and myelosuppression. There are no published single-agent data for SKI 2053R in the Western literature, but a combination schedule was established for SKI 2053R with 5-FU in 64 chemotherapy-naïve patients with gastric cancer. The platinum compound was given intravenously at a dose of 400 mg/m 2 every 3 weeks, together with 5-FU 1000 mg/m 2 on days 1-5. A 30% (range 22-38%) response rate was reported in abstract form [27] .
Topoisomerase inhibitors Irinotecan
Irinotecan is a semisynthetic topoisomerase I inhibitor with well-established antitumour activity in gastrointestinal and other malignancies and is now one of the new standard agents for first-and second-line treatment of colorectal cancer. The drug is commonly associated with myelosuppression, cholinergic effects, gastrointestinal toxicity and other side effects. Irinotecan has been studied in a number of recent trials in gastric cancer. In an early report of a small series of nine nonpretreated patients with advanced adenocarcinoma of the stomach or the gastroesophageal junction, it was found to be highly toxic and side effects included severe diarrhoea, neutropenia, vomiting, lethargy and renal toxicity [28] . These findings were not confirmed by other investigators in larger studies with single-agent irinotecan or irinotecan-based combinations (Table 4 ). According to the published trials, irinotecan appears to have moderate but reproducible activity as a single agent in chemotherapy-naïve patients with gastric cancer.
The results of a number of combination trials based on irinotecan are currently available, with response rates in nonpretreated patients ranging from 18 to 62% (Table 5) .
Further irinotecan-based combinations have been developed for combined modality treatment and concomitant irradiation approaches. The definitive role of the topoisomerase-I inhibitor in metastatic gastric cancer will be clarified as soon as results of ongoing phase III studies become available.
Rubitecan
Rubitecan [9-nitro-20(S)-camptothecin, RFS-2000] is an insoluble topoisomerase I-inhibiting agent in advanced stages of clinical development with considerable cytotoxic activity in a wide array of preclinical models including various human tumor xenografts. Rubitecan has the potential advantage of oral bioavailability. A recent phase II study in patients with gastric cancer showed that the compound is well tolerated and active with a 15% response rate among 20 evaluable patients who had received no more than one prior chemotherapy regimen [42] .
Taxanes Paclitaxel
Paclitaxel, the prototype taxane compound which interferes with tubulin assembly and disassembly, has been studied extensively both in pre-treated and non-pretreated patients with gastric cancer. The safety profile of paclitaxel was found to be very similar to that in patients with other tumour types. A modest single-agent activity was observed in various phase II trials (Table 6 ). Responses in non-pretreated patients were in the range 4-17%, and activity was also seen in pre-treated patients.
Paclitaxel can be combined with a variety of well-established compounds for treatment of gastric cancer, as demonstrated in a number of trials (Table 7) . Of note is the considerable response rate documented both in chemotherapy-naïve and pre-treated patients.
Weekly paclitaxel is also evaluated with concurrent radiation in patients with locally advanced gastric cancer.
Docetaxel
Docetaxel, another tubulin-inhibiting agent of the taxane family with broad anti-tumour activity, has also been studied extensively in patients with advanced gastric carcinoma. The toxicity profile of doxetaxel in gastric cancer is very comparable with that seen in other tumour types. The level of response to single-agent docetaxel appears to be similar to that reported with paclitaxel (Table 8) .
More recently, assessment of docetaxel combination chemotherapy has demonstrated substantial activity in this tumour type. The therapeutic value of docetaxel-based chemotherapy of gastric cancer is currently being widely investigated in several randomised trials, and response data are very similar to paclitaxel combinations as reported above (Table 9) . Docetaxel has also been used in sequential chemotherapy after weekly PELF (CDDP/5-FU/epirubicin/6S-leucovorin/ gluthathion) in advanced gastric cancer, as recently reported by an Italian group [67] . In this trial docetaxel improved the clinical outcome after initial combination chemotherapy in 26.5% of patients. According to the investigators, the sequential application of docetaxel gained major responses with manageable toxicity. The combination of taxanes with CDDP and 5-FU (or an oral substitute) has become very popular in the United States, where it is associated with good response rates and effective palliation of symptoms [2] .
BMS-247550
BMS-247550 is a novel epothilone B derivative, which induces tubulin polymerisation and G 2 /M arrest leading to apoptosis of cancer cells. The drug appears to have preclinical activity in taxane-sensitive and -resistant cell tumours. Among 23 gastric cancer patients pre-treated with one taxanebased chemotherapy regimen, a 10% partial response rate and a considerable number of patients with disease stabilisation was noted [68] . The drug was given at a dose of 50 mg/m 2 every 3 weeks. Severe toxicities included fatigue, anorexia, nausea/vomiting and neuropathy. 
Anthracyclines

Liposomal doxorubicin
Caelyx is a stealth liposome-encapsulated anthracycline that has recently been introduced in the treatment of solid tumours including breast and ovarian cancer. The drug achieved only one response among 17 non-pretreated patients with gastric cancer at a dose of 45 mg/m 2 i.v. given every 4 weeks [69] , and is unlikely to be explored further in this tumour type.
Matrix metalloproteinase inhibitors Marimastat
Marimastat is a specific inhibitor of matrix metalloproteinases. The oral compound is generally well tolerated and mainly associated with musculoskeletal toxicity. In an exploratory trial, the drug was given at a daily dose of 25 or 100 mg over a period of 28 days to 35 non-pretreated patients with the primary tumour in situ, immediately followed by endoscopic re-evaluation [70] . Objective responses were not reported, but there was some evidence of increased fibrotic cover and less haemorrhage of the tumours. In phase III, marimastat was compared to placebo in 369 pre-treated and non-pretreated patients with gastric cancer [71] . A significant improvement in progression-free survival and a trend towards improved overall survival was documented for the experimental compound.
Discussion
The interest in chemotherapy for gastric cancer has increased substantially over the past few years. Considerable effort has been undertaken in comparing and refining treatment schedules, following demonstration that chemotherapy improves survival and quality of life in metastatic disease when compared with supportive care strategies. The number of potentially active new drugs has increased, and many investigators have been evaluating combinations of older and newer agents. More active drugs and innovative combinations hold promise for improved palliation and extension of survival not only in advanced disease, but also in a potentially curative adjuvant or preoperative setting. Among the newer agents, the oral fluoropyrimidines, taxanes, irinotecan and oxaliplatin appear to be very relevant candidates. Numerous studies with these and other new agents are ongoing and the results will help clarify their future role in the treatment of gastric cancer. Further clinical research is certainly needed to define the optimal role for these therapies, with specific focus on comparative phase II/ III trials. Every effort should be made to enter patients with advanced gastric cancer into prospective clinical trials.
